BRIBF
Brii Biosciences Limited·Healthcare
0.16
0.000%(+0.00)
Close PriceLast Updated: — ET
52W L: $0.1652W H: $0.26
BRIBF NEWS
prnewswire.com
22h ago
Brii Bio Presents Late-Breaking Data from Its Phase 2 ENSURE Study at EASL Congress 2026, Further Supporting the Potential Role of BRII-179 in Achieving Durable Immunological Control of HBV
- Final results from the ENSURE study demonstrate that the addition of elebsiran resulted in a higher functional cure rate compared with pegylated interferon alfa (PEG-IFNα) alone - Data from Cohort 4 suggested that participants responding to prior BRII ‑ 179 treatment achieved the most robust functional cure outcomes, further supporting its potential clinical benefit - Data from an ENSURE translational study demonstrated that BRII ‑ 179-induced epitope-mismatched CD4+ T cells and HBs ‑ specific B cell maturation were associated with enhanced HBsAg loss following curative treatment, offering additional insights into its potential mechanisms DURHAM, N.C. and BEIJING, May 27, 2026 /PRNewswire/ -- Brii Biosciences Limited ("Brii Bio" or the "Company", stock code: 2137.HK), a biotechnology company developing therapies to improve patient health and choice across diseases with high unmet medical need, today announced end-of-study (EOS) data from Cohorts 1-4 of its Phase 2 ENSURE study at the European Association for the Study of the Liver (EASL) Congress 2026 in Barcelona, Spain.
prnewswire.com
Apr 26
Brii Bio Presents Cross-Study Analysis of Post-Treatment HBsAg Rebound at APASL 2026
- Participants achieving HBsAg loss with pegylated interferon alfa (PEG-IFNα) ± elebsiran or BRII-179 demonstrated favorable off-treatment clinical outcomes, with most HBsAg rebounds
seekingalpha.com
Mar 20
Brii Biosciences Limited (BRIBF) Q4 2025 Earnings Call Transcript
Brii Biosciences Limited (BRIBF) Q4 2025 Earnings Call Transcript
prnewswire.com
Mar 19
Brii Biosciences Provides Corporate Updates and Reports Full Year 2025 Financial Results
Advancing HBV Functional Cure Toward Key Phase 2b Data Readouts Increasing Discovery Efforts to Drive Long-term Value Creation Strong Cash Position Supporting Strategic Priorities Upcoming Conference Calls: English Session: March 20 at 8:30 p.m. HKT / 8:30 a.m.
